AI assistant
Sending…
TYK Medicines, Inc — Earnings Release 2001
Apr 12, 2002
50580_rns_2002-04-12_bb33309b-71a2-4b59-bb55-b2fde0218a46.htm
Earnings Release
Open in viewerOpens in your device viewer
Listed Company Information
![]() |
| GUANGDONG TANN<01058> - Results Announcement (Summary) Guangdong Tannery Limited announced on 12/4/2002: (stock code: 1058) Year end date: 31/12/2001 Currency: HKD Auditors' Report: Neither Review of Interim Report by: N/A (Audited) (Audited) Last Current Corresponding Period Period from 1/1/2001 from 1/1/2000 to 31/12/2001 to 31/12/2000 ('000) ('000) Turnover : 764,929 721,141 Profit/(Loss) from Operations : (62,571) (92,196) Finance cost : (15,221) (21,555) Share of Profit/(Loss) of Associates : (154) (965) Share of Profit/(Loss) of Jointly Controlled Entities : N/A N/A Profit/(Loss) after Tax & MI : (72,283) (84,550) % Change over Last Period : N/A EPS/(LPS)-Basic : (13.79 cents) (16.13 cents) -Diluted : N/A N/A Extraordinary (ETD) Gain/(Loss) : N/A N/A Profit/(Loss) after ETD Items : (72,283) (84,550) Final Dividend per Share : Nil Nil (Specify if with other options) : - - B/C Dates for Final Dividend : N/A Payable Date : N/A B/C Dates for Annual General Meeting : 30/5/2002 to 31/5/2002 bdi. Other Distribution for Current Period : N/A B/C Dates for Other Distribution : N/A Remark: EARNINGS/(LOSS) PER SHARE The calculation of basic loss per share is based on the net loss attributable to shareholders for the year of HK$72,283,000 (2000: HK$84,550,000), and the weighted average of 524,154,000 (2000: 524,154,000) ordinary shares in issue during the year. No diluted loss per share is presented for the years ended 31 December 2001 and 2000 as the dilution effect from the exercise of share options of the Company is anti-dilutive. |
More from TYK Medicines, Inc
Regulatory Filings
2026
Jun 2
Regulatory Filings
2026
May 31
Proxy Solicitation & Information Statement
2026
May 22
AGM Information
2026
May 22
Proxy Solicitation & Information Statement
2026
May 22
Regulatory Filings
2026
May 6
Annual Report
2026
Apr 29
Share Issue/Capital Change
2026
Apr 8
Regulatory Filings
2026
Apr 2
Annual Report
2026
Mar 30
